CN106420809B - A kind of ophthalmologic operation perfusion liquid - Google Patents

A kind of ophthalmologic operation perfusion liquid Download PDF

Info

Publication number
CN106420809B
CN106420809B CN201610787864.1A CN201610787864A CN106420809B CN 106420809 B CN106420809 B CN 106420809B CN 201610787864 A CN201610787864 A CN 201610787864A CN 106420809 B CN106420809 B CN 106420809B
Authority
CN
China
Prior art keywords
extract
ophthalmologic operation
low
perfusion liquid
mulberries
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610787864.1A
Other languages
Chinese (zh)
Other versions
CN106420809A (en
Inventor
李慧慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinmin health management Limited by Share Ltd
Original Assignee
ZHEJIANG CHIMING PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZHEJIANG CHIMING PHARMACEUTICAL CO Ltd filed Critical ZHEJIANG CHIMING PHARMACEUTICAL CO Ltd
Priority to CN201610787864.1A priority Critical patent/CN106420809B/en
Publication of CN106420809A publication Critical patent/CN106420809A/en
Application granted granted Critical
Publication of CN106420809B publication Critical patent/CN106420809B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605—Morus (mulberry)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Abstract

The invention discloses a kind of ophthalmologic operation perfusion liquid, by mass percentage, following component is included in the ophthalmologic operation perfusion liquid：Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2·6H2O 0.03%.The present invention has preferably booster action to postoperative recovery, can effectively prevent cataract in vitretomized eyes in addition to the effect with general balanced salt solution.

Description

A kind of ophthalmologic operation perfusion liquid
Technical field
The present invention relates to a kind of ophthalmologic operation assistant product, more particularly to a kind of ophthalmologic operation perfusion liquid.
Background technology
With the development of modern micro-surgical instruments, ophthalmologic operation generally uses microinstrument, intraocular surgery technology day Become to improving and ripe.Generally carry out in situation of all-level hospitals cataract extraction, vitrectomy is also begun to big-and-middle Type hospital progressively carries out, and its quantity increases year by year, has saved many blindness or the eyes close to blindness.Vitrectomy, It is one of ophthalmology routine operation, the treatment for a variety of eye diseases such as detachment of retina, vitreous hemorrhage.In surgical procedure In, for balance intraocular pressure, the use of intraocular irrigating solution is essential.Conventional intraocular perfusion liquid is ophthalmology balanced salt solution, and this is molten Liquid during preparation and use with the saturation of the air, contain higher partial pressure of oxygen（21.2kPa）, in surgical procedure, with glass The removal of glass body tissue, it is eliminated for the iris action of retinal vessel oxygen disperse, while using partial pressure containing higher oxygen in art Intraocular irrigating solution so that crystalline lens is exposed in high keto sectional pressure environment, accelerate lenticular oxidative damage, induce postoperative white The generation of cataract or glaucoma.
In recent years, with the more and more extensive Clinical practice of intraocular irrigating solution, its security is also more and more weighed Depending on.Research shows, chemical composition, osmotic pressure, the buffer capacity of ion and temperature of the perfusion liquid used in intraocular surgery etc. Material impact can be produced to the 26S Proteasome Structure and Function of the eye inner tissues such as post-operative cornea, crystalline lens, retina.Conventional ophthalmologic operation Perfusion liquid is simple balanced salt solution, little to postoperative recovery booster action.Therefore, correct selection one kind is more conformed to The perfusion liquid of intraocular normal physiological context, it will effectively reduce postoperative complications.
The content of the invention
It is an object of the invention to provide a kind of ophthalmologic operation perfusion liquid, except the effect with general balanced salt solution Outside, there is preferably booster action to postoperative recovery, can effectively prevent cataract in vitretomized eyes.
The technical solution adopted for the present invention to solve the technical problems is：
A kind of ophthalmologic operation perfusion liquid, by mass percentage, includes following component in the ophthalmologic operation perfusion liquid：Chlorine Change sodium 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2 ·6H2O 0.03%。
Preferably, by mass percentage, following component is also included in the ophthalmologic operation perfusion liquid：Three hydration acetic acid Sodium 0.39%, sodium citrate 0.17%.
Preferably, by mass percentage, following component is also included in the ophthalmologic operation perfusion liquid：Disodium hydrogen phosphate 0.042%, sodium acid carbonate 0.21%, glucose 0.092%, oxidized form of glutathione 0.018%.Contain oxidized form of glutathione in formula Contribute to Post operation to provide the apparent cornea visual field, containing oxidized form of glutathione, disodium hydrogen phosphate, bicarbonate component, make It is compatible with endothelium more preferably, and glucose provides nutrition.The main buffer substance of disodium hydrogen phosphate, is also the main component of aqueous humor. The perfusion liquid of potassium-containing hydrogen salt does not change corneal thickness, HCO3 -Active transport contributes to the performance of endothelial cell pumping function, It can also maintain, extend human corneal endothelial cells current potential, contribute to the performance of retinal function.Glucose ocular tissue passes through grape Glycometabolism produces energy, maintains the transparent and retina normal function of cornea and crystal.Glutathione is aqueous humor and crystal Natural constituent, plays the role of to resisting oxidation free radical, can effectively remove the toxic work produced in ophthalmic surgical procedures Free radical, can prevent the oxidative damage of the mercapto groups in albumen.Oxidized form of glutathione is through retina, choroid and angle Reduced glutathione can be converted into quickly after the intake of film endothelial cell.
Preferably, by mass percentage, following component is also included in the ophthalmologic operation perfusion liquid：Zinc lactate 0.015%, aloe barbadensis Miller polysaccharide 0.02%, VB5 0.01%, Ilex pubescens extract 0.02%.
Add zinc lactate in the present invention to be mainly used in providing zinc ion, for preventing the surface of a wound from expanding, vitamin B5 is used to promote Enter wound healing.Aloe barbadensis Miller polysaccharide is used for ophthalmologic operation perfusion liquid by the present invention first, and it has preferable bacteria resistance function, Infection is prevented, the healing of wound can be effectively facilitated, have repairing effect well to the wound of ophthalmologic operation.While aloe barbadensis Miller Polysaccharide has very strong antiallergic effect, and other compositions can be prevented to the stimulation of eye.Ilex pubescens extract can be antiviral Infection, clearing liver cholagogic improves the blood circulation of part tissue of eye, and postoperative eye vision restoration and wound are recovered to have preferably to aid in Effect.
Preferably, the preparation method of the Ilex pubescens extract is as follows：Ilex pubescens is freeze-dried, it is then super in low temperature Low-temperature grinding to 300-500 mesh obtains ilex pubescens low temperature powder at 0-4 DEG C in atomizer, by ilex pubescens low temperature powder and mass concentration 90% ethanol solution is according to 1g：10mL solid-liquid ratio is well mixed, and ultrasonic power is ultrasonic extraction 15min, Ran Houjia under 450w Heat extracts 3-5h to 45 DEG C, and filtering and impurity removing adds the activated carbon for accounting for filtrate weight 1-3% into filtrate, stirs 1-2 hours and takes off Color, crosses and filters out the filter vacuum of activated carbon and be concentrated under reduced pressure recovery ethanol, obtain Ilex pubescens extract.
Preferably, by mass percentage, following component is also included in the ophthalmologic operation perfusion liquid：Mulberries extract 0.035%, fresh extract from pine needles 0.03%, vitamin C 0.01%, sargassum fusifome extract 0.018%.Mulberries extract nutrition is rich Richness, liver-kidney tonifying, improving eyesight recovers have preferably booster action to postoperative eye vision restoration and wound.Fresh extract from pine needles battalion Support abundant, rich in various trace elements and amino acid, calm the nerves, improving eyesight, improve the function of capillary, improve immunity, make group Rejuvenation is knitted, having preferably booster action is recovered to postoperative eye vision restoration and wound.Sargassum fusifome extraction is with the addition of in raw material Thing, its composition is mainly brown algae polyphenols, with very strong anti-oxidation function, also with antitumor activity, antiviral activity, deodorization Activity etc..Vitamin C can reduce anaphylactoid generation, with very strong anti-oxidation function, suppress enzymatic browning, and protection is easy Oxide, deoxygenation and free radical.The present invention is used cooperatively using sargassum fusifome extract with vitamin C, is had in terms of total antioxidation There is good cooperative effect, improve fungistatic effect, promote wound healing, prevent the generation of postoperative cataract.
Preferably, the preparation method of the mulberries extract is：Mulberries are freeze-dried, it is then broken in low-temperature submicron powder Low-temperature grinding to 100-200 mesh obtains mulberries low temperature powder at 0-4 DEG C in machine, by mulberries low temperature powder and deionized water according to 1g：15mL Solid-liquid ratio be well mixed, be then heated to refluxing extraction 1-3 times, filtering and impurity removing, filter vacuum is concentrated under reduced pressure into original volume 20%, the filtrate weight 1-3% accounted for after concentration activated carbon is added into the filtrate after concentration, stirs 1-2 hours and decolourizes, cross and filter out Activated carbon, obtains mulberries extract.
Preferably, the preparation method of the fresh extract from pine needles is as follows：Fresh pine needle is freeze-dried, it is then super in low temperature Low-temperature grinding to 200-400 mesh obtains fresh pine needle low temperature powder at 0-4 DEG C in atomizer, by fresh pine needle low temperature powder and mass concentration 90% ethanol solution is according to 1g：10mL solid-liquid ratio is well mixed, and is then heated to 50 DEG C, extracts 3-5h, filtering and impurity removing, to Added in filtrate and account for filtrate weight 1-3% activated carbon, stirred 1-2 hour and decolourize, cross filter out activated carbon filter vacuum depressurize it is dense Retract and receive ethanol, obtain fresh extract from pine needles.
Preferably, the preparation method of the sargassum fusifome extract is as follows：Sargassum fusifome is freeze-dried, it is then super in low temperature Low-temperature grinding to 200-400 mesh obtains sargassum fusifome low temperature powder at 0-4 DEG C in atomizer, and sargassum fusifome low temperature powder is pressed with 95% ethanol According to 1g：10mL solid-liquid ratio mixing, is heated to extracting 1-2h at 55 DEG C, filters, filter vacuum is concentrated under reduced pressure into the 20% of original volume Concentrate is obtained, the activated carbon for accounting for dope weight 1-3% is added into concentrate, stirs 1-2 hours and decolourizes, cross and filter out activated carbon；Most Concentrate chloroform 3 times, is then extracted with ethyl acetate 3 times afterwards, and evaporated under reduced pressure removes ethyl acetate and obtains sargassum fusifome extraction Thing.
The beneficial effects of the invention are as follows：In addition to the effect with general balanced salt solution, have preferably to postoperative recovery Ground booster action, can effectively prevent cataract in vitretomized eyes.
Embodiment
Below by specific embodiment, technical scheme is described in further detail.
In the present invention, if not refering in particular to, raw material and equipment used etc. is commercially available or commonly used in the art. Method in following embodiments, is the conventional method of this area unless otherwise instructed.
Embodiment 1：
A kind of ophthalmologic operation perfusion liquid, component is as follows：Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2 ·6H2O 0.03%, sodium acetate trihydrate 0.39%, sodium citrate 0.17%, water for injection surplus.
Embodiment 2：
A kind of ophthalmologic operation perfusion liquid, component is as follows：Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2 ·6H2O 0.03%, disodium hydrogen phosphate 0.042%, sodium acid carbonate 0.21%, glucose 0.092%, oxidized form paddy The sweet peptide 0.018% of Guang, water for injection surplus, pH7.4.
Embodiment 3：
A kind of ophthalmologic operation perfusion liquid, component is as follows：Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2 ·6H2O 0.03%, sodium acetate trihydrate 0.39%, sodium citrate 0.17%, zinc lactate 0.015%, Curacao Aloe polysaccharide 0.02%, VB5 0.01%, Ilex pubescens extract 0.02%, water for injection surplus.
Embodiment 4：
A kind of ophthalmologic operation perfusion liquid, component is as follows：Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2 ·6H2O 0.03%, disodium hydrogen phosphate 0.042%, sodium acid carbonate 0.21%, glucose 0.092%, oxidized form paddy The sweet peptide 0.018% of Guang, zinc lactate 0.015%, aloe barbadensis Miller polysaccharide 0.02%, VB5 0.01%, Ilex pubescens extract 0.02%, note Penetrate and use water surplus.
Embodiment 5：
A kind of ophthalmologic operation perfusion liquid, component is as follows：Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2 ·6H2O 0.03%, sodium acetate trihydrate 0.39%, sodium citrate 0.17%, mulberries extract 0.035% is fresh Extract from pine needles 0.03%, vitamin C 0.01%, sargassum fusifome extract 0.018%, water for injection surplus.
Embodiment 6：
A kind of ophthalmologic operation perfusion liquid, component is as follows：Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2 ·6H2O 0.03%, sodium acetate trihydrate 0.39%, sodium citrate 0.17%, zinc lactate 0.015%, Curacao Aloe polysaccharide 0.02%, VB5 0.01%, Ilex pubescens extract 0.02%, mulberries extract 0.035%, fresh extract from pine needles 0.03%, Vitamin C 0.01%, sargassum fusifome extract 0.018%, water for injection surplus.
Embodiment 7：
A kind of ophthalmologic operation perfusion liquid, component is as follows：Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2 ·6H2O 0.03%, disodium hydrogen phosphate 0.042%, sodium acid carbonate 0.21%, glucose 0.092%, oxidized form paddy The sweet peptide 0.018% of Guang, mulberries extract 0.035%, fresh extract from pine needles 0.03%, vitamin C 0.01%, sargassum fusifome extract 0.018%, water for injection surplus.
Embodiment 8：
A kind of ophthalmologic operation perfusion liquid, component is as follows：Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2 ·6H2O 0.03%, disodium hydrogen phosphate 0.042%, sodium acid carbonate 0.21%, glucose 0.092%, oxidized form paddy The sweet peptide 0.018% of Guang, zinc lactate 0.015%, aloe barbadensis Miller polysaccharide 0.02%, VB5 0.01%, Ilex pubescens extract 0.02%, mulberry Shen extracts 0.035%, fresh extract from pine needles 0.03%, vitamin C 0.01%, sargassum fusifome extract 0.018%, more than water for injection Amount.
The preparation method of the Ilex pubescens extract is as follows：Ilex pubescens is freeze-dried, then in the broken machine of low-temperature submicron powder Low-temperature grinding to 300-500 mesh obtains ilex pubescens low temperature powder at middle 0-4 DEG C, by ilex pubescens low temperature powder and the ethanol of mass concentration 90% Solution is according to 1g：10mL solid-liquid ratio is well mixed, and ultrasonic power is ultrasonic extraction 15min under 450w, is then heated to 45 DEG C, 3-5h is extracted, filtering and impurity removing adds the activated carbon for accounting for filtrate weight 1-3% into filtrate, stirs 1-2 hours and decolourizes, crosses and filter out work The filter vacuum of property charcoal is concentrated under reduced pressure recovery ethanol, obtains Ilex pubescens extract.
The preparation method of the mulberries extract is：Mulberries are freeze-dried, then 0-4 DEG C in the broken machine of low-temperature submicron powder Lower low-temperature grinding to 100-200 mesh obtains mulberries low temperature powder, by mulberries low temperature powder and deionized water according to 1g：15mL solid-liquid ratio It is well mixed, refluxing extraction is then heated to 1-3 times, filtering and impurity removing, filter vacuum is concentrated under reduced pressure into the 20% of original volume, to dense The filtrate weight 1-3% accounted for after concentration activated carbon is added in filtrate after contracting, stirs 1-2 hours and decolourizes, cross and filter out activated carbon, Obtain mulberries extract.
The preparation method of the fresh extract from pine needles is as follows：Fresh pine needle is freeze-dried, then in the broken machine of low-temperature submicron powder Low-temperature grinding to 200-400 mesh obtains fresh pine needle low temperature powder at middle 0-4 DEG C, by fresh pine needle low temperature powder and the ethanol of mass concentration 90% Solution is according to 1g：10mL solid-liquid ratio is well mixed, and is then heated to 50 DEG C, extracts 3-5h, and filtering and impurity removing is added into filtrate Account for filtrate weight 1-3% activated carbon, stir 1-2 hour and decolourize, the filter vacuum that mistake filters out activated carbon is concentrated under reduced pressure recovery second Alcohol, obtains fresh extract from pine needles.
The preparation method of the sargassum fusifome extract is as follows：Sargassum fusifome is freeze-dried, then in the broken machine of low-temperature submicron powder Low-temperature grinding to 200-400 mesh obtains sargassum fusifome low temperature powder at middle 0-4 DEG C, by sargassum fusifome low temperature powder and 95% ethanol according to 1g： 10mL solid-liquid ratio mixing, is heated to extracting 1-2h at 55 DEG C, filters, and filter vacuum is concentrated under reduced pressure into the 20% of original volume and obtains dense Contracting liquid, the activated carbon for accounting for dope weight 1-3% is added into concentrate, is stirred 1-2 hours and is decolourized, crosses and filter out activated carbon；It is last dense Contracting liquid chloroform 3 times, is then extracted with ethyl acetate 3 times, and evaporated under reduced pressure removes ethyl acetate and obtains sargassum fusifome extract.
The ophthalmologic operation perfusion liquid of the present invention is mainly used in the operated eye for needing to be irrigated.In ophthalmologic operation, make For the perfusion liquid outside intraocular or eye, most long infusion time must not exceed 60 minutes.After patient's use after 50 operated eyes, After-operation response can be reduced, the morphosis and physiological function of basic holding ocular tissue, effect are substantially better than physiological saline, and clinic should With working well, there is preferably booster action to postoperative recovery, can effectively prevent cataract in vitretomized eyes, nothing Allergic reaction occurs.
Animal experiment：
Experimental subjects：Healthy 15 age of cleaning grade SD rat children mouses 90, body weight 25g or so, male and female and half.
Method：90 SD rats are randomly divided into Normal group, model control group and treatment group of the present invention, every group 30. The preparation method of selenite induced catatract rat model is：2mmol/L sodium selenites are subcutaneously injected in 15 age in days SD rat children mouses nape parts Physiological saline（20μmol/kg）, the next day 1 time, continuous 5 days.Intraperitoneal injection of saline during Normal group modeling；Model comparison Group is while selenite induced catatract model is induced, daily intraperitoneal injection of saline（5ml/kg）, continuous 5 days；Present invention treatment Group is while selenite induced catatract is induced, daily intraperitoneal injection perfusion liquid of the present invention（5ml/kg）, continuous 5 days.
As a result：
Len's opacity is observed：1st after modeling is successful, 3,5,7 days observation lenticular muddinesses of each group animal Degree.Carry out seeing under eyes mydriasis, slit-lamp microscope using compound tropicamide eye drops in each time point each group rat Examine phacoscotasmus situation.Rats in normal control group crystalline lens in whole experiment process remains transparent, model control group Crystalline lens is completely muddy, and the crystalline lens for the treatment of group 30% of the present invention is completely muddy, lesser extent.Compared with model control group, this hair The generation of bright treatment group's phacoscotasmus is relative to be delayed, and turbidity is significantly lower than model control group.
The 7th day after success modeling, cervical dislocation puts to death each group rat, extracts eyeball, after being rinsed with physiological saline, Eyeball is splitted from the way of escape under microscope, wall of eyeball and vitreum is removed, crystalline lens is taken out, PBS, ice-water bath condition is added after weighing Lower homogenate, prepares 1000r/min centrifugation 10min under the conditions of tissue homogenate, 4 DEG C, goes supernatant biochemical assay to use each examination SOD, CAT activity in agent box detection crystalline lens.
Treatment group SOD activity of the present invention is in 19.12U/mg or so, and CAT activity is in 6.32 U/mg or so；Normal group SOD activity is in 21.36U/mg or so, and CAT activity is in 7.14 U/mg or so.Model control group SOD activity is left in 7.43U/mg The right side, CAT activity is in 2.46 U/mg or so.Each numerical value for the treatment of group SOD, CAT activity of the present invention does not have compared with Normal group Notable difference, model control group each numerical value of SOD, CAT activity compared with Normal group is significantly reduced；With model control group phase Than SOD, CAT activity substantially increase in treatment group's crystalline lens of the present invention.
Embodiment described above is a kind of preferably scheme of the present invention, not makees any formal to the present invention Limitation, also has other variants and remodeling on the premise of without departing from the technical scheme described in claim.

Claims (5)

1. a kind of ophthalmologic operation perfusion liquid, it is characterised in that by mass percentage, the component of the ophthalmologic operation perfusion liquid is such as Under：Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2 ·6H2O 0.03%, sodium acetate trihydrate 0.39%, sodium citrate 0.17%, mulberries extract 0.035%, fresh extract from pine needles 0.03%, vitamin C 0.01%, sargassum fusifome is carried Take thing 0.018%, water for injection surplus.
2. a kind of ophthalmologic operation perfusion liquid, it is characterised in that by mass percentage, the component of the ophthalmologic operation perfusion liquid is such as Under：Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2 ·6H2O 0.03%, sodium acetate trihydrate 0.39%, sodium citrate 0.17%, zinc lactate 0.015%, aloe barbadensis Miller polysaccharide 0.02%, VB5 0.01%, Ilex pubescens extract 0.02%, mulberries extract 0.035%, fresh extract from pine needles 0.03%, vitamin C 0.01%, sargassum fusifome extract 0.018%, note Penetrate and use water surplus.
3. a kind of ophthalmologic operation perfusion liquid according to claim 2, it is characterised in that the preparation side of the mulberries extract Method is：Mulberries are freeze-dried, then in the broken machine of low-temperature submicron powder at 0-4 DEG C low-temperature grinding to 100-200 mesh to obtain mulberries low Wen Fen, by mulberries low temperature powder and deionized water according to 1g：15mL solid-liquid ratio is well mixed, and is then heated to refluxing extraction 1-3 Secondary, filtering and impurity removing, filter vacuum is concentrated under reduced pressure into the 20% of original volume, and the filtrate accounted for after concentration is added into the filtrate after concentration Weight 1-3% activated carbon, stirs 1-2 hours and decolourizes, cross and filter out activated carbon, obtain mulberries extract.
4. a kind of ophthalmologic operation perfusion liquid according to claim 2, it is characterised in that the preparation of the fresh extract from pine needles Method is as follows：Fresh pine needle is freeze-dried, then low-temperature grinding to 200-400 mesh is obtained at 0-4 DEG C in the broken machine of low-temperature submicron powder Fresh pine needle low temperature powder, by fresh pine needle low temperature powder and the ethanol solution of mass concentration 90% according to 1g：10mL solid-liquid ratio mixing is equal It is even, 50 DEG C are then heated to, 3-5h is extracted, filtering and impurity removing adds the activated carbon for accounting for filtrate weight 1-3% into filtrate, stirs 1- Decolourize within 2 hours, cross and filter out the filter vacuum of activated carbon and be concentrated under reduced pressure recovery ethanol, obtain fresh extract from pine needles.
5. a kind of ophthalmologic operation perfusion liquid according to claim 2, it is characterised in that the preparation of the sargassum fusifome extract Method is as follows：Sargassum fusifome is freeze-dried, then low-temperature grinding to 200-400 mesh is obtained at 0-4 DEG C in the broken machine of low-temperature submicron powder Sargassum fusifome low temperature powder, by sargassum fusifome low temperature powder and 95% ethanol according to 1g：10mL solid-liquid ratio mixing, is heated to extracting at 55 DEG C 1-2h, filtering, filter vacuum be concentrated under reduced pressure into original volume 20% concentrate, into concentrate add account for dope weight 1-3% Activated carbon, stir 1-2 hour decolourize, mistake filter out activated carbon；Last concentrate chloroform 3 times, then uses ethyl acetate Extraction 3 times, evaporated under reduced pressure removes ethyl acetate and obtains sargassum fusifome extract.
CN201610787864.1A 2016-08-31 2016-08-31 A kind of ophthalmologic operation perfusion liquid Active CN106420809B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610787864.1A CN106420809B (en) 2016-08-31 2016-08-31 A kind of ophthalmologic operation perfusion liquid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610787864.1A CN106420809B (en) 2016-08-31 2016-08-31 A kind of ophthalmologic operation perfusion liquid

Publications (2)

Publication Number Publication Date
CN106420809A CN106420809A (en) 2017-02-22
CN106420809B true CN106420809B (en) 2017-08-08

Family

ID=58163763

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610787864.1A Active CN106420809B (en) 2016-08-31 2016-08-31 A kind of ophthalmologic operation perfusion liquid

Country Status (1)

Country Link
CN (1) CN106420809B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024044342A1 (en) * 2022-08-26 2024-02-29 Marizyme, Inc. Antioxidant-containing eye drop formulations and methods of prevention and/or treatment using same

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108671270A (en) * 2018-05-25 2018-10-19 爱博诺德（北京）医疗科技有限公司 Viscoelastic agent material with redox characteristic
CN109771370B (en) * 2019-02-28 2021-03-30 厦门大学 Anterior chamber perfusate for intraocular surgery and application thereof
CN111001010B (en) * 2019-12-28 2022-09-02 潍坊医学院附属医院 External eye operation flushing fluid and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101062051A (en) * 2007-05-25 2007-10-31 北京大学人民医院 Injection liquid for vitreous cutting operation and the preparing method thereof
CN101125149B (en) * 2007-09-19 2010-09-29 温州医学院眼视光研究院 Ophthalmic operating special-purpose colored perfusate
DK2780022T3 (en) * 2011-11-14 2019-07-15 Astellas Inst For Regenerative Medicine PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS AND USES THEREOF

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024044342A1 (en) * 2022-08-26 2024-02-29 Marizyme, Inc. Antioxidant-containing eye drop formulations and methods of prevention and/or treatment using same

Also Published As

Publication number Publication date
CN106420809A (en) 2017-02-22

Similar Documents

Publication Publication Date Title
CN106420809B (en) A kind of ophthalmologic operation perfusion liquid
CN100522162C (en) New pranoprofen eye drops and its preparation method
CN101416741A (en) Health-care food for relieving visual fatigue
RU2465872C1 (en) Method of prevention and treatment of excessive scarring after anti-glaucoma operation
CN105617350A (en) Extraction method of sheep sclera collagen, ophthalmic gel and preparation method thereof
Hill Corneal vascularization after cataract extraction by zonulysis
CN102512467A (en) Ophthalmic preparation of panax notoginseng saponins and preparation method thereof
CN105832977A (en) Eye-protecting nourishing solution and preparation method thereof
Barraquer Enzymatic zonulolysis in lens extraction
CN103006695A (en) Intraocular perfusate and preparation method thereof
CN104814977B (en) A kind of ophthalmic flexibility hydrosol assistant agent
CN107375206A (en) A kind of high biocidal property pearl eyesight improvement drops
Fankhauser et al. Neodymium Q-switched YAG laser lysis of iris lens synechiae
CN101804057A (en) Chuagxiongzine ophthalmic preparation
Cavallini et al. Bimanual microphacoemulsification and Acri. Smart intraocular lens implantation combined with vitreoretinal surgery
CN111956737A (en) Traditional Chinese medicine for nourishing eyes, preparation method and Chinese-style eye nourishing equipment
RU2303457C1 (en) Method for applying enzymotherapy
RU2698588C1 (en) Method for simulating filtration pads using scleral-conjunctival dissector
RU2345740C1 (en) Method of dystrophic eye diseases treatment by means of medicinal mud remedy "relict-05"
CN100387260C (en) Eye medicine for treating senile cataract and its pH value regulating method and preparing process
CN106074626A (en) A kind of alleviate dry and astringent antibacterial liquid of eye and preparation method thereof
SU1398859A1 (en) Method of extracapsular extraction of immature cataract
CN116115708A (en) Eye drop for treating myopia, astigmatism and presbyopia and preparation method thereof
Beteg et al. Cataracts surgery in dog by extracapsular extraction, mini-nuc method.
RU2135127C1 (en) Solution "vizitin" for prophylaxis and treatment of patient with sickness and damage of cornea

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: 318020 No. 888 north courtyard Road, Huangyan District, Taizhou, Zhejiang

Patentee after: Jinmin health management Limited by Share Ltd

Address before: 318020 No. 888 north courtyard Road, Huangyan District, Taizhou, Zhejiang

Patentee before: Zhejiang Chiming Pharmaceutical Co.,Ltd.

CP01 Change in the name or title of a patent holder